American Association of Clinical Urologists, Inc.

In this K-Cast video series, Neal Shore, MD, describes current standards in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and provides an overview of data from the PROfound ...

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

"This study is significant because it really emphasizes the importance of early detection of both BPH and ED, because knowing that information can really preserve men's quality of life," says Olivia ...

In this video, Bridget F. Koontz, MD, FASTRO, highlights the role that PSMA-PET imaging has played in enabling more targeted treatment for prostate cancer. Koontz is radiation oncologist and the ...

The panelist discusses how 68gallium prostate-specific membrane antigen-11 (PSMA-11) gozetotide is most useful in PET-CT imaging for detecting and staging prostate cancer.

"We found an increased association with AKI or acute kidney injury in the group receiving testosterone replacement therapy," said Evan Panken, MD. In this video, Evan Panken, MD, discusses the ...

Patients are turning to TikTok for TRT information, but many videos omit long-term negative impacts. Most videos analyzed were created by companies advertising supplements, with only one physician ...

Bel-sar is a virus drug conjugate using HPV virus-like particles conjugated to a cytotoxic drug for targeted cancer cell destruction. The therapy targets heparan sulfate proteoglycans on cancer cells, ...

CREST, POTOMAC, KEYNOTE, and ALBAN trials investigate PD-1/PD-L1 inhibitors for BCG-naive bladder cancer patients, focusing on efficacy and safety. Routes of administration vary, with some trials ...

"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of ...

The ARANOTE trial enables personalized cancer treatment, allowing oncologists to tailor therapy based on individual patient needs and clinical situations. Flexibility in the trial design accommodates ...